1. Scrip
  2. >>Therapy Areas
  3. >>Respiratory

Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III

 
• By Peter Chang

Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.

Racetrack
The rush is on to advance development in IPF

A bevy of early-stage IPF candidates showed preliminary signals of efficacy and safety in several sessions during the American Thoracic Society (ATS) International Conference in San Diego May 18-23 and now the drugs are in a race to Phase III.

Some of the presentations were updates from top-line data, but there also were new data to support later-stage programs. Scrip spoke with Kevin Gibson, medical director for the Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease at the University of Pittsburgh, who spoke in various venues at the conference

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Respiratory

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.